Pharmacokinetics of buprenorphine following intravenous administration in dogs

American Journal of Veterinary Research

Volumn 69, Issue 6, 2008, Pages 722-727

  Krotscheck, Ursula ^a   Boothe, Dawn M ^b   Little, Amy A ^a  

^a Department of Obstetrics Gynecology   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; MALE; MEAN RESIDENCE TIME; NONHUMAN; PAIN ASSESSMENT; PRESCRIPTION; RADIOIMMUNOASSAY; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; BUPRENORPHINE; DOGS; FEMALE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE;

ANIMALIA; CANIS FAMILIARIS;

EID: 45949101617     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.6.722     Document Type: Article

References (43)

1. Mok MS, Lippmann M, Steen SN. Multidose/observational, comparative clinical analgetic evaluation of buprenorphine. J Clin Pharmacol 1981;21:323-329.
2. Tigerstedt I, Tammisto T. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain. Acta Anaesthesiol Scand 1980;24:462-468.
3. Wang RI, Johnson RP, Robinson N, et al. The study of analgesics following single and repeated doses. J Clin Pharmacol 1981;21:121-125.
4. Lascelles BD, Capner CA, Waterman-Pearson AE. Current British veterinary attitudes to perioperative analgesia for cats and small mammals. Vet Rec 1999;145:601-604.
5. Watson AD, Nicholson A, Church DB, et al. Use of anti-inflammatory and analgesic drugs in dogs and cats. Aust Vet J 1996;74:203-210.
6. Joubert KE. The use of analgesic drugs by South African veterinarians. J S Afr Vet Assoc 2001;72:57-60.
7. Garrett ER, Chandran VR. Pharmacokinetics of morphine and its surrogates. X: analyses and pharmacokinetics of buprenorphine in dogs. Biopharm Drug Dispos 1990;11:311-350.
8. Muir WW, Hubbell JAE, Skarda RT, et al. Handbook of veterinary anesthesia. 3rd ed. St Louis: Mosby Inc, 2000.
9. Hendrix P, Hansen B. Acute pain management. In: Bonagura J, ed. Kirk's current veterinary therapy: XIII small animal practice. Philadelphia: WB Saunders, 2000;57-61.
10. Woodman FJ. Topical lidocaine-prilocaine versus lidocaine for neonatal circumcision: a randomized controlled trial. Obstet Gynecol l999;93:775-779.
11. Bartlett AJ, Lloyd-Jones JG, Rance MJ, et al. The radioimmunoassay of buprenorphine. Eur J Clin Pharmacol 1980;18:339-345.
12. Hand CW, Baldwin D, Moore RA, et al. Radioimmunoassay of buprenorphine with iodine label: analysis of buprenorphine and metabolites in human plasma. Ann Clin Biochem 1986;23:47-53.
13. Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990;64:276-282.
14. Hambrook JM, Rance MJ. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW ed. Opiates and endogenous opioid peptides. Amsterdam: Elsevier, 1976;295-301.
15. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-545.
16. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297-326.
17. Registry of toxic effects of chemical substances [database online]. San Leandro, Calif. MDL Information Systems Inc, 2002. Available at: www.mdl.com/products/predictive/rtecs/index.jsp. Accessed Jul 1, 2007.
18. Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977;60:547-554.
19. Yassen A, Olofsen E, Dahan A, et al. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 2005;313:1136-1149.
20. Darland T, Heinricher MM, Grandy DK. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 1998;21:215-221.
21. Hara N, Minami T, Okuda-Ashitaka E, et al. Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol 1997;121:401-408.
22. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995;270:792-794.
23. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-695.
24. Bloms-Funke P, Gillen C, Schuettler AJ, et al. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000;21:1141-1146.
25. Yu S, Zhang X, Sun Y, et al. Pharmacokinetics of buprenorphine after intravenous administration in the mouse. J Am Assoc Lab Anim Sci 2006;45:12-16.
26. Gopal S, Tzeng TB, Cowan A. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur J Pharm Sci 2002;15:287-293.
27. Taylor PM, Robertson SA, Dixon MJ, et al. Morphine, pethidine and buprenorphine disposition in the cat. J Vet Pharmacol Ther 2001;24:391-398.
28. Robertson SA, Lascelles BD, Taylor PM, et al. PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. J Vet Pharmacol Ther 2005;28:453-460.
29. Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004;43:329-340.
30. Toutain PL, Bousquet-Melou A. Plasma clearance. J Vet Pharmacol Ther 2004;27:415-425.
31. Toutain PL, Bousquet-Melou A. Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther 2002;25:460-463.
32. Skingle M, Tyers MB. Further studies on opiate receptors that mediate antinoception: tooth pulp stimulation in the dog. Br J Pharmacol 1980;70:323-327.
33. Robinson TM, Kruse-Elliott KT, Markel MD, et al. A comparison of transdermal fentanyl versus epidural morphine for analgesia in dogs undergoing major orthopedic surgery. J Am Anim Hosp Assoc 1999;35:95-100.
34. Robertson SA, Taylor PM, Sear JW, et al. Relationship between plasma concentrations and analgesia after intravenous fentanyl and disposition after other routes of administration in cats. J Vet Pharmacol Ther 2005;28:87-93.
35. Toutain PL, Bousquet-Melou A. Plasma terminal half-life. J Vet Pharmacol Ther 2004;27:427-439.
36. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002;113:746-750.
37. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 1985; 57:192-196.
38. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995;272:505-510.
39. Ebling WF, Lee EN, Stanski DR. Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil. Anesthesiology 1990;72:650-658.
40. Bouw MR, Xie R, Tunblad K, et al. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 2001;134:1796-1804.
41. Pontani RB, Vadlamani NL, Misra AL. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 1985;15:287-297.
42. Shiue CY, Bai LQ, Teng RR, et al. A comparison of the brain uptake of N-(cyclopropyl[11C]methyl)norbuprenorphine ([11C]buprenorphine) and N-(cyclopropyl[11C]methyl)nordi prenorphine ([11C]diprenorphine) in baboon using PET. Int J Rad Appl Instrum B 1991;18:281-288.
43. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006;104:1232-1242.